NEUROCRINE BIOSCIENCES INC: PHASE 3 KINECT DCP STUDY EVALUATING EFFICACY, SAFETY OF VALBENAZINE DID NOT MEET PRIMARY OR KEY SECONDARY ENDPOINTS

Reuters · 3d ago

Please log in to view news